索拉非尼和沙利度胺对肝癌患者血清中VEGF-C、VEGF-D及微血管密度的影响

目的：探讨索拉非尼和沙利度胺这两种不同的化疗药物，对肝癌患者血清中VEGF-C、VEGF—D及微血管密度的影响。方法：将患者分成3组，每纽16例。对照组采用常规治疗并服用安慰剂；索拉非尼和沙利度胺这两个组患者中，前者服用索拉非尼400mg／次，2次／d，治疗6个月；后者服用沙利度胺每日服200mg，每周增加200mg／d，直至最大剂量每日600mg，至少服用4月。ELISA检测患者血清中VEGF-C、VEGF-D；免疫组织化学检测肝癌组织中微血管密度。结果：对照组患者血清中VEGF-C的水平为210ng／ml，索拉非尼组患者血清中VEGF—C的水平为132ng／ml，而沙利度胺组患者血清中VEGF—C的水平为186ng／ml。与对照组相比，索拉非尼组和沙利度胺组患者血清中VEGF—C的水平均降低。对照组患者血清中VEGF—D的水平为322ng／ml，索拉非尼组患者血清中VEGF—D的水平为217ng／ml，而沙利度胺组患者血清中VEGF—D的水平为256ng／ml。与对照组相比，索拉非尼组和沙利度胺组患者血清中VEGF—D的水平均降低。索拉非尼组患者血清中VEGF—D的水平明显低于沙利度胺高（P〈0．05）。对照组肝癌组织MVD为（44．32±5．16）个，索拉非尼组患者肝癌组织MVD为（21．75±1．49）个，而沙利度胺组患者肝癌组织MVD为（34．78±2．31）个。结论：多靶点化疗药物索拉非尼对肝癌患者血清中VEGF—C、VEGF—D及微血管密度的影响最大，深入探讨其作用机制．可为其肝癌患者提供新的化疗方案。

Effect of Sorafenib and Thalidomide on the VEGF-C, VEGF-D and Microvessel Density of Patients with Liver Cancer

Objective： To discover the effect of Sorafenib and thalidomide on the VEGF-C, VEGF-D and microvessel density of patients with liver cancer. Methods： The patients were divided into 3 groups of 16 cases. Control group were treated with conventional method and placebo; The other two groups took sorafenib and thalidomide. The former group took sorafenib 400 mg/time, twice/d for 6 months; the latter took thalidomide 200mg/day, increased 200mg/d every week, up to the maximum daily dosage of 600mg which lasted at least four months. ELISA were used to detect the levels of serum VEGF-C, VEGF-D;immunohistochemical detect the microvessel density of tumor tissue. Results： VEGF-C level of Serum was 210neffml in the control group, while that of sorafenib group and thalidomide group was 132ng/ml and 186ng / ml, respectively. Compared with the control group, serum VEGF-C levels in patients of sorafenib and thalidomide group were lowered. The level of VEGF-D of serum was 322ng/ml in the control group, while that of sorafenib group and thalidomide group was 217ng/ml and 256ng / ml, respectively. Compared with the control group, serum VEGF-D levels in patients of sorafenib and thalidomide group were lowered. Serum VEGF-D level of Sorafenib group was significantly lower than that of thalidomide group （P 〈0.05）. MVD of the tumor tissue in control group were 44.32 ±5.16, while those in Sorafenib group and thalidomide group were 21.75 ±1.49 and 34.78±2.31, respectively. Conclusion： The multi-target chemotherapy drugs, sorafenib could affect the serum VEGF-C, VEGF-D and the microvessel density of patients with liver cancer. The further research on its mechanism may provide a new chemotherapy for those patients.